5336-08-3

Basic information

• Product Name: D(+)-Ribonic acid gamma-lactone
• Synonyms: D-RIBOSE-LACTONE;D-(+)-RIBONIC ACID GAMMA-LACTON;D(+)-RIBONIC ACID GAMMA-LACTONE;D-(+)-RIBONIC ACID G-LACTONE;D-(+)-RIBONIC GAMMA-LACTONE;D(+)-RIBONO-1,4-LACTONE;D-RIBONO-1,4-LACTONE;D-(+)-RIBONO-GAMMA-LACTONE
• CAS NO: 5336-08-3
• Molecular Formula: C₅H₈O₅
• Molecular Weight: 148.11
• EINECS: 226-256-5
• Product Categories: Sugars, Carbohydrates & Glucosides;13C & 2H Sugars;Biochemistry;Ribose;Sugar Acids;Sugars;Dextrins、Sugar & Carbohydrates;Carbohydrates & Derivatives;Inhibitors
• Mol File: 5336-08-3.mol
• Article Data: 24

Chemical Properties

• Melting Point: 85-87 °C(lit.)
• Boiling Point: 188.68°C (rough estimate)
• Flash Point: 162.8°C
• Appearance: White to Pale Yellow/Powder
• Density: 1.2336 (rough estimate)
• Vapor Pressure: 8.77E-07mmHg at 25°C
• Refractive Index: 18 ° (C=1, H2O)
• Storage Temp.: -20°C Freezer
• Solubility: H2O: 0.1 g/mL, clear
• PKA: 12.10±0.60(Predicted)
• Water Solubility: soluble
• Stability: Stable
• BRN: 82057
• CAS DataBase Reference: D(+)-Ribonic acid gamma-lactone(CAS DataBase Reference)
• NIST Chemistry Reference: D(+)-Ribonic acid gamma-lactone(5336-08-3)
• EPA Substance Registry System: D(+)-Ribonic acid gamma-lactone(5336-08-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 5336-08-3(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Solid

Uses

Different sources of media describe the Uses of 5336-08-3 differently. You can refer to the following data:
1. A sugar lactone as inhibitor of β-galactosidase of E. coli.
2. Important chiral synthon
3. D-ribono-1,4-lactone is a compound useful in organic synthesis.

Definition

ChEBI: A five-membered form of ribonolactone having D-configuration.

Purification Methods

Purify D-(+)-ribonic acid--lactone by recrystallisation from EtOAc. The tribenzoate has m 54-56o (from AcOH), [] D 25 +27o (c 2.37, Me2NCHO), and the 3,5-O-benzylidene derivative has m 230-231.5o (needles from Me2CO-pet ether) and [] D 25 -177o (CHCl3). [Chen & Joulié J Org Chem 49 2168 1984, Zinner & Voigt J Carbohydr Research 7 38 1968.]

InChI:InChI=1/C5H8O5/c6-1-2-3(7)4(8)5(9)10-2/h2-4,6-8H,1H2/t2?,3-,4-/m1/s1

Upstream product

• 5346-83-8 calcium D-ribonate 
• 10257-32-6 D-ribose 
• 488-81-3 Adonitol 
• 85846-80-6 5-O-benzyl-2,3-O-isopropylidene-D-ribono-1,4-lactone 
• 92512-33-9 (3R,4S,5R)-5-((tert-butyldiphenylsilyloxy)methyl)-3,4-dihydroxydihydrofuran-2(3H)-one 
• 157453-65-1 (3R,4S,5R)-5-(tert-butyldimethylsilyloxymethyl)-3,4-dihydroxy-dihydrofuran-2-one 
• 41162-32-7 2,3,5-tri-O-acetyl-D-ribonic acid γ-lactone 
• 78508-91-5 5-benzyloxy-2-hydroxy-3-hydroxy-D-ribonolactone 
• 30725-00-9 2,3-O-isopropylidene-D-ribonic-γ-lactone 
• 532-20-7 D-Ribose 

Downstream Products

• 110533-61-4 D-erythro-2-deoxy-pentonic acid-(N'-phenyl-hydrazide) 
• 5588-13-6 1-Benzyl-2-D-ribonoyl-hydrazin 
• 92493-90-8 1-(α-Methylphenethyl)-2-D-ribonoylhydrazin 
• 93432-56-5 1-<4-Dimethylamino-benzyl>-2-D-ribonoyl-hydrazin 
• 642-98-8 D-ribonic acid 
• 77270-40-7 2,3-O-<(4-methoxyphenyl)ethylidene>ribonic acid γ-lactone 
• 27304-20-7 2,3-O-cyclohexylidene-γ-D-ribonolactone 
• 84911-43-3 (3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)-dihydrofuran-2(3H)-one 
• 134877-40-0 3,4-O-benzylidene-D-ribonic-δ-lactone 
• 90108-48-8 2,3-O-Benzylidene-5-bromo-5-deoxy-D-ribonic Acid γ-Lactone 
• 20603-45-6 3,4-O-Benzylidene-D-(+)-ribonic acid δ-lactone 
• 15397-14-5 C₂₆H₂₀O₈ 
• 90108-55-7 5-O-Acetyl-D-ribono-γ-lactone 
• 108-28-1 protoanemonin 

Relevant articles and documents

-

-

Novel synthesis method for synthesizing remdesivir

The invention discloses a novel synthesis method for synthesizing remdesivir. According to the synthesis method disclosed by the invention, D-ribose is taken as a raw material and is subjected to a series of reactions such as oxidation, cyclohexanone protection, silanization protection, substitution, substitution, deprotection, coupling, deprotection and the like to synthesize the remdesivir. The post-treatment operation is optimized, and the method has the advantages of being short in reaction time, high in yield, low in cost, suitable for industrial production and the like. The structure of the remdesivir provided by the invention is shown in the specification.

Antioxidant composition comprising marliolide derivatives

The present invention relates to a marliolide derivative and an antioxidant composition containing the same as an active component, wherein the marliolide derivative increases the expression of a transcription factor Nrf2 that regulates the expression of an antioxidant-related protein without cytotoxicity, thereby increasing the expression of HO-1 and NQO1, which are antioxidant-related proteins. In addition, since the marliolide derivative is confirmed to inhibit the oxidation of DNA and lipids induced by TPA that induces oxidative stress, a composition containing the marliolide derivative can be provided as the antioxidant composition.(AA) Compound 1 (10 andmu;M)COPYRIGHT KIPO 2019